UPDATE: Jefferies Raises PT on Eli Lilly & Co. as Least-Preferred Name
In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated an Underperform rating on Eli Lilly & Co. (NYSE: LLY), and slightly raised the price target from $43.00 to $44.00.
In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.”
Eli Lilly & Co. closed on Tuesday at $56.74.
Latest Ratings for LLY
|Nov 2016||Atlantic Equities||Downgrades||Overweight||Neutral|
|Nov 2016||BMO Capital||Downgrades||Outperform||Market Perform|
|Sep 2016||Goldman Sachs||Upgrades||Neutral||Buy|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.